Trial Profile
Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2023
Price :
$35
*
At a glance
- Drugs Momelotinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences; GSK
- 16 Jun 2023 Planned End Date changed from 1 Dec 2026 to 31 Dec 2026.
- 16 Jun 2023 Planned primary completion date changed from 1 Dec 2026 to 31 Dec 2026.
- 16 Jun 2023 This study has been completed in Austria, according to European Clinical Trials Database.